Anti-SARS-CoV-2 Spike Glycoprotein RBD IgG ELISA Kit
CAY-502110-96 96 Well
Synonyms: Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein Receptor Binding Domain IgG
Data Sheet: 
SDS:
SDS:
Shipment
-20
Long Term Storage
-20
Shelf Life
365
Description
Cayman’s Anti-SARS-CoV-2 Spike Glycoprotein RBD IgG ELISA Kit is an enzyme-linked immunosorbent assay that can be used for the qualitative assessment of the presence of antibodies against the SARS-CoV-2 spike glycoprotein RBD in human plasma and serum. In general, while PCR positivity indicates the presence of viral antigens, this serological assay indicates the presence of IgG antibodies against the SARS-CoV-2 spike glycoprotein RBD, which occurs in the weeks following SARS-CoV-2 infection. The IgG response measured in this kit does not differentiate neutralizing antibodies, which specifically interrupt the interaction between the spike glycoprotein RBD and the ACE2 receptor on the host cell, from non-neutralizing antibodies that bind to the RBD. A positive control is included in this kit to provide a cut-off for seropositivity.
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
